<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294525</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT03294525</nct_id>
  </id_info>
  <brief_title>Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders</brief_title>
  <official_title>Clinical Psychopharmacology Division</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is a multi-center, prospective cohort study. The study's total targeted&#xD;
      enrollment is 400 first-episode patients with major depressive disorder (MDD) and 400 healthy&#xD;
      controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four hundred patients with a primary diagnosis of depression and HAMD-17 scores ≥14 at&#xD;
      baseline visit are to be assigned to one of the second-generation antidepressant drugs,&#xD;
      including escitalopram, duloxetine, mirtazapine, paroxetine, sertraline, etc based on&#xD;
      investigators' clinical practice. Initial treatment consists of a 8-week course with one of&#xD;
      these monotherapies. Patients who meet criteria for full remission are followed for a&#xD;
      22-month follow-up phase to monitor for depression recurrence. Patients who do not remit are&#xD;
      offered another 8 weeks of acute treatment, including combination therapy or switching to&#xD;
      other antidepressant based on investigators' clinical practice. The clinical assessment&#xD;
      (Hamilton Depression Rating Scale(HAMD)/ Clinical general impression (CGI) /the Positive and&#xD;
      Negative Affect Schedule (PANAS) /subtypes of depression, Dimensional Anhedonia Rating Scale&#xD;
      (DARS) , etc), early life stress, neuropsychological test, and biological examination (MRI,&#xD;
      genetics, neurochemistry, and immunology) were conducted to identify the biomarkers&#xD;
      associated with diagnosis, treatment efficacy prediction of depression. Among the 400&#xD;
      patients, about 100 patients receive MRI scans at baseline and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in HAMD total scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>reduction more than 50% was regarded as response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>remision</measure>
    <time_frame>8 weeks</time_frame>
    <description>HAMD total score less than 7</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram-for MDD</arm_group_label>
    <description>Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine-for MDD</arm_group_label>
    <description>Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirtazepine-for MDD</arm_group_label>
    <description>Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other antidepressant-for MDD</arm_group_label>
    <description>Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram Pill</intervention_name>
    <description>escitalopram 10~20mg/day</description>
    <arm_group_label>Escitalopram-for MDD</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>duloxetine 30~120mg/day</description>
    <arm_group_label>Duloxetine-for MDD</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine Pill</intervention_name>
    <description>Mirtazapine 15~45mg/day</description>
    <arm_group_label>Mirtazepine-for MDD</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other Antidepressants</intervention_name>
    <arm_group_label>other antidepressant-for MDD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples were collected by venepuncture.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with major depressive disorder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients with depression&#xD;
&#xD;
          -  The inclusion criteria for depressed patients were: male or female outpatients aged&#xD;
             between 18 and 55 years old&#xD;
&#xD;
          -  Currently in acute depressive episode&#xD;
&#xD;
          -  Total HAMD-17 score≥14 at baseline visit.&#xD;
&#xD;
          -  The diagnosis of depression was confirmed by a trained psychiatrists using the&#xD;
             Mini-International Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          -  The patients participating in imaging scans should additionally satisfy: not taking&#xD;
             psychiatric drugs within last two weeks (except for benzodiazepine) or fluoxetine last&#xD;
             one month&#xD;
&#xD;
          -  Not receiving ECT within last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to complete the questionnaire and psychological assessment independently&#xD;
&#xD;
          -  Significant cognitive impairments determined by system mental examination and&#xD;
             inability to sign an informed consent form&#xD;
&#xD;
          -  Past or presently suffering from other psychiatric disorders, alcohol and drug&#xD;
             dependence&#xD;
&#xD;
          -  Suffering from major physical diseases, such as cardiovascular and cerebrovascular&#xD;
             diseases, respiratory diseases, kidney disease, cancer and so on; personality disorder&#xD;
&#xD;
          -  Intellectual disabilities&#xD;
&#xD;
          -  Suicidal behavior&#xD;
&#xD;
          -  Being participating in other studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianmei Si, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth hospital of beijing university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunai Su, PhD</last_name>
    <phone>010-62723761</phone>
    <email>suyunai@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of mental health, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianmei Si, PhD.</last_name>
      <phone>8610-82801960</phone>
      <email>si.tian-mei@163.com</email>
    </contact>
    <investigator>
      <last_name>Tianmei Si, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Si Tianmei</investigator_full_name>
    <investigator_title>Clinical Psychopharmacology Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

